HomeCompareDTCFF vs EQR

DTCFF vs EQR: Dividend Comparison 2026

DTCFF yields 500.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTCFF wins by $61399.48M in total portfolio value
10 years
DTCFF
DTCFF
● Live price
500.00%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61399.52M
Annual income
$44,063,578,515.70
Full DTCFF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — DTCFF vs EQR

📍 DTCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTCFFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTCFF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DTCFF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTCFF
Annual income on $10K today (after 15% tax)
$42,500.00/yr
After 10yr DRIP, annual income (after tax)
$37,454,041,738.34/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, DTCFF beats the other by $37,454,038,491.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTCFF + EQR for your $10,000?

DTCFF: 50%EQR: 50%
100% EQR50/50100% DTCFF
Portfolio after 10yr
$30699.78M
Annual income
$22,031,791,167.65/yr
Blended yield
71.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

DTCFF
No analyst data
Altman Z
-31.5
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTCFF buys
0
EQR buys
0
No recent congressional trades found for DTCFF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTCFFEQR
Forward yield500.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$61399.52M$40.5K
Annual income after 10y$44,063,578,515.70$3,819.61
Total dividends collected$59892.67M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DTCFF vs EQR ($10,000, DRIP)

YearDTCFF PortfolioDTCFF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$60,700$50,000.00$11,248$547.57+$49.5KDTCFF
2$348,594$283,644.86$12,701$666.53+$335.9KDTCFF
3$1,895,372$1,522,376.89$14,405$814.59+$1.88MDTCFF
4$9,763,990$7,735,942.00$16,413$999.84+$9.75MDTCFF
5$47,691,977$37,244,507.54$18,795$1,232.92+$47.67MDTCFF
6$221,049,019$170,018,603.23$21,639$1,527.95+$221.03MDTCFF
7$972,993,924$736,471,474.07$25,057$1,903.80+$972.97MDTCFF
8$4,070,762,075$3,029,658,575.98$29,197$2,385.87+$4070.73MDTCFF
9$16,201,818,371$11,846,102,950.68$34,250$3,008.70+$16201.78MDTCFF
10$61,399,524,173$44,063,578,515.70$40,467$3,819.61+$61399.48MDTCFF

DTCFF vs EQR: Complete Analysis 2026

DTCFFStock

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full DTCFF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this DTCFF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTCFF vs SCHDDTCFF vs JEPIDTCFF vs ODTCFF vs KODTCFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.